Form 8-K - Current report:
SEC Accession No. 0001213900-24-020389
Filing Date
2024-03-06
Accepted
2024-03-06 13:55:31
Documents
15
Period of Report
2024-03-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0201306-8k_immucell.htm   iXBRL 8-K 27494
2 AMENDING AGREEMENT BETWEEN THE COMPANY AND NORBROOK LABORATORIES LIMITED DATED A ea0201306ex10-1_immucell.htm EX-10.1 31127
  Complete submission text file 0001213900-24-020389.txt   235314

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE iccc-20240304.xsd EX-101.SCH 3015
4 XBRL LABEL FILE iccc-20240304_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE iccc-20240304_pre.xml EX-101.PRE 22359
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0201306-8k_immucell_htm.xml XML 3492
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 24725264
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)